Abstract
The clinical application of apomorphine, a dopamine receptor agonist for treating Parkinsons disease, is limited by its instability and the need for frequent injections. In the present work, apomorphine was encapsulated within liposomes to protect it from degradation and enhance the permeability across the blood-brain barrier (BBB). Stearylamine was used to produce a positive surface charge for the liposomes. The liposomal systems with different compositions were characterized by the mean size, zeta potential, drug encapsulation percentage, stability, and in vitro release characteristics. PEGylated liposomes and liposomes incorporating Brij 78 showed a size of 130~160 nm. When Tween 80 was added to the liposomes, the vesicle size increased to > 260 nm. Apomorphine was successfully entrapped by liposomes with an encapsulation percentage of > 70%, with the systems containing Brij 78 showing the highest level of 99%. The loading of apomorphine into liposomes resulted in slower release behavior compared to the drug in an aqueous solution. In comparison to free drug, apomorphine in PEGylated liposomes exhibited greater stability in plasma. The in vivo brain uptake of PEGylated liposomes after an intravenous bolus injection into rats was monitored by in vivo real-time bioluminescence imaging for 1 h. The results showed that the uptake of PEGylated liposomes into the brain was rapid and prolonged. PEGylated liposomes may offer a promising strategy for targeting apomorphine to the brain. This opens up new opportunities for treating Parkinsons disease.
Keywords: Apomorphine, PEGylated liposomes, blood-brain barrier, brain targeting, drug delivery systems, Nonionic Surfactants, Real-time Imaging, Parkinson's disease
Current Nanoscience
Title: PEGylated Liposomes Incorporated with Nonionic Surfactants as an Apomorphine Delivery System Targeting the Brain: In Vitro Release and In Vivo Real-time Imaging
Volume: 7 Issue: 2
Author(s): Shu-Hui Hsu, Saleh A. Al-Suwayeh, Chih-Chieh Chen, Chen-Hsien Chi and Jia-You Fang
Affiliation:
Keywords: Apomorphine, PEGylated liposomes, blood-brain barrier, brain targeting, drug delivery systems, Nonionic Surfactants, Real-time Imaging, Parkinson's disease
Abstract: The clinical application of apomorphine, a dopamine receptor agonist for treating Parkinsons disease, is limited by its instability and the need for frequent injections. In the present work, apomorphine was encapsulated within liposomes to protect it from degradation and enhance the permeability across the blood-brain barrier (BBB). Stearylamine was used to produce a positive surface charge for the liposomes. The liposomal systems with different compositions were characterized by the mean size, zeta potential, drug encapsulation percentage, stability, and in vitro release characteristics. PEGylated liposomes and liposomes incorporating Brij 78 showed a size of 130~160 nm. When Tween 80 was added to the liposomes, the vesicle size increased to > 260 nm. Apomorphine was successfully entrapped by liposomes with an encapsulation percentage of > 70%, with the systems containing Brij 78 showing the highest level of 99%. The loading of apomorphine into liposomes resulted in slower release behavior compared to the drug in an aqueous solution. In comparison to free drug, apomorphine in PEGylated liposomes exhibited greater stability in plasma. The in vivo brain uptake of PEGylated liposomes after an intravenous bolus injection into rats was monitored by in vivo real-time bioluminescence imaging for 1 h. The results showed that the uptake of PEGylated liposomes into the brain was rapid and prolonged. PEGylated liposomes may offer a promising strategy for targeting apomorphine to the brain. This opens up new opportunities for treating Parkinsons disease.
Export Options
About this article
Cite this article as:
Hsu Shu-Hui, A. Al-Suwayeh Saleh, Chen Chih-Chieh, Chi Chen-Hsien and Fang Jia-You, PEGylated Liposomes Incorporated with Nonionic Surfactants as an Apomorphine Delivery System Targeting the Brain: In Vitro Release and In Vivo Real-time Imaging, Current Nanoscience 2011; 7 (2) . https://dx.doi.org/10.2174/157341311794653686
DOI https://dx.doi.org/10.2174/157341311794653686 |
Print ISSN 1573-4137 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6786 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Glucose in the Pathogenesis of Alzheimers Disease Revisited:What Does it Tell us About the Therapeutic use of Lithium?
Central Nervous System Agents in Medicinal Chemistry IL-10 Producing Regulatory B Cells in Mice and Humans: State of the Art
Current Molecular Medicine Silencing the Transcription Factor FOSL1 in Hyperproliferative HaCaT Cells Makes Them Susceptible to IFN-γ
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Stem Cell Ageing and Apoptosis
Current Pharmaceutical Design Update on ICOS: A Possible Target for Turning-Off Autoimmunity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) A Common Biological Mechanism in Cancer and Alzheimers Disease?
Current Alzheimer Research Cellular and Physiological Effects of Ganoderma lucidum (Reishi)
Mini-Reviews in Medicinal Chemistry Vitamin D in Acute Kidney Injury
Inflammation & Allergy - Drug Targets (Discontinued) Peripheral TRPV1 Receptors As Targets for Drug Development: New Molecules and Mechanisms
Current Pharmaceutical Design Maintenance of Gastrointestinal Glucose Homeostasis by the Gut-Brain Axis
Current Protein & Peptide Science Antiproliferative Effect of HSP90 Inhibitor Y306zh Against Pancreatic Cancer is Mediated by Interruption of AKT and MAPK Signaling Pathways
Current Cancer Drug Targets Recent Development of Hydrogen Sulfide Therapeutics in the Treatment of Cardiovascular Diseases
Current Topics in Medicinal Chemistry The Effects of Insulin and Insulin-Like Growth Factors on Tumor Vascularization: New Insights of Insulin-Like Growth Factor Family in Cancer
Current Medicinal Chemistry Progresses and Challenges in Optimization of Human Pluripotent Stem Cell Culture
Current Stem Cell Research & Therapy Emerging Adenoviral Vectors for Stable Correction of Genetic Disorders
Current Gene Therapy Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease
Current Stem Cell Research & Therapy Immune Response to Helper Dependent Adenoviral Mediated Liver Gene Therapy: Challenges and Prospects
Current Gene Therapy The Role of Thrombomodulin in Atherosclerosis: From Bench to Bedside
Cardiovascular & Hematological Agents in Medicinal Chemistry Nicotinamide Phosphoribosyltransferase (Nampt): A Link Between NAD Biology, Metabolism, and Diseases
Current Pharmaceutical Design Cachexia and Herbal Medicine: Perspective
Current Pharmaceutical Design